Federal Government Sues Pharmacy Benefit Managers Over Rising Insulin Prices for Diabetic Patients

The federal government has initiated legal action against major pharmacy benefit managers (PBMs) over practices that allegedly inflate insulin prices for diabetic patients. The Federal Trade Commission (FTC) filed a lawsuit on Friday against Caremark, Express Scripts, and OptumRx, which manage about 80% of US prescriptions. The FTC accuses these companies of engaging in anticompetitive practices that contribute to rising drug costs.

PBMs are responsible for managing prescription drug coverage for insurers, large employers, and other clients. They create formularies, which are lists of covered medications, and negotiate rebates on drug prices. According to the FTC, the rebate practices of these companies have led to artificially high list prices, impacting individuals without insurance or those with high-deductible plans.

Impact on Insulin Prices

The FTC claims that the current system favours insulins with high list prices while excluding cheaper alternatives. This situation allegedly benefits PBMs and their group purchasing organisations financially, while patients face increased out-of-pocket expenses for insulin. Insulin is a crucial medication for people with diabetes, making its affordability a significant concern.

For years, PBMs have faced criticism from politicians, patients, and others. However, PBMs argue they play a vital role in controlling drug costs and claim to pass most negotiated discounts to their clients. Despite this defence, the FTC maintains that the system prioritises expensive insulins over more affordable options.

Responses from Accused Companies

Caremark responded by stating that it negotiates substantial discounts for its clients to make insulin more affordable for members. Express Scripts criticised the FTC's actions as politically motivated and accused it of ignoring facts instead of focusing on consumer protection. OptumRx dismissed the FTC's accusations as baseless, asserting that PBMs serve as a counterbalance to pharmaceutical companies' unchecked power to set and raise drug prices.

The lawsuit highlights ongoing tensions between regulators and PBMs over drug pricing practices. As the case unfolds, it may bring further scrutiny to how prescription drug prices are determined and managed in the United States.